Author

A. Szczepanski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:virus· 1

Frequent Co-Authors

K. Pyrc· 4 shared A. Dabrowska· 3 shared A. Milewska· 2 shared E. Barreto-Duran· 2 shared K. Owczarek· 2 shared M. Ochman· 2 shared P. Botwina· 2 shared A. Czarna· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

K. Pyrc

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

POU2AF2/C11orf53 functions as a co-activator of POU2F3 by maintaining chromatin accessibility and enhancer activity

L. Wang, A. Szczepanski, N. Tsuboyama, Z. Zhao

This study identifies POU2AF2 as a co-activator of POU2F3 in SCLC, showing it maintains chromatin accessibility and enhancer activity essential for tuft cell marker expression.

bioRxiv · Mar 17, 2022 · PreprintCancer Biology

Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.

A. Dabrowska, A. Szczepanski, P. Botwina, N. Mazur-Panasiuk, H. Jirincova, L. Rabalski, T. Zajic, G. Popowicz, K. Pyrc

This study evaluates the efficacy of antivirals against SARS-CoV-2 variants, including Omicron, Delta, and the early 2020 isolate.

bioRxiv · Dec 21, 2021 · PreprintMicrobiology

Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses

V. Napolitano, A. Dabrowska, K. Schorpp, A. Mourao, E. Barreto-Duran, M. Benedyk, P. Botwina, S. Brandner, M. Bostock, Y. Chykunova, A. Czarna, G. Dubin, T. Frohlich, M. Hoelscher, M. Jedrysik, , K. Pyrc

This study identifies acriflavine as a potent inhibitor of SARS-CoV-2 and other betacoronaviruses, effective in cellular models, in vivo, and ex vivo.

bioRxiv · Mar 20, 2021Microbiology

HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV

A. Milewska, Y. Chi, A. Szczepanski, E. Barreto-Duran, K. Liu, D. Liu, X. Guo, Y. Ge, J. Li, L. Cui, M. Ochman, M. Urlik, S. Rodziewicz-Motowidlo, F. Zhu, K. Szczubialka, , K. Pyrc

This paper evaluates HTCC as a potential inhibitor for SARS-CoV-2 and MERS-CoV, highlighting its antiviral activity against highly pathogenic coronaviruses.

bioRxiv · Mar 29, 2020 · PreprintMicrobiology

Replication of SARS-CoV-2 in human respiratory epithelium

A. Milewska, A. Kula-Pacurar, J. Wadas, A. Suder, A. Szczepanski, A. Dabrowska, K. Owczarek, M. Ochman, T. Stacel, Z. Rajfur, P. P. Labaj, W. Branicki, K. Pyrc

The paper presents a human airway epithelium model for studying SARS-CoV-2 replication and drug assessment, highlighting its potential as an alternative to animal models and Vero E6 cells.

bioRxiv · Mar 20, 2020Microbiology